INTEGRA LIFESCIENCES HOLDINGS CORP IART revenue by segment, product and geography
In its fiscal year ending 2025-12-31, INTEGRA LIFESCIENCES HOLDINGS CORP reported revenue across 2 business segments; the largest, Codman Specialty Surgical, was $1.2B, 73.4% of the filed sum (+5.0% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Codman Specialty Surgical$1.2B73.4%+5.0% yoy
- Tissue Technologies$435M26.6%-6.9% yoy
Members sum to the consolidated $1.64B for this period.
- United States$1.2B73.7%+1.0% yoy
- Asia Pacific$189M11.6%+7.2% yoy
- Europe$163M9.9%+2.6% yoy
- Rest Of The World$78.6M4.8%-5.0% yoy
Members sum to the consolidated $1.64B for this period.
- Specialty Surgery$309M73.9%no prior
- Tissue Reconstruction$109M26.1%no prior
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.